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Background:  Uncertainty exists concerning the factors affecting platelet reactivity in patients after percutaneous coronary intervention 
treated with clopidogrel regimen. We evaluated the association of platelet reactivity with endothelial function and arterial stiffness in patients 
after percutaneous coronary intervention receiving clopidogrel treatment.
methods:  We enrolled 150 patients with stable CAD receiving clopidogrel regimen (75mg/d), one month after percutaneous coronary 
intervention. Endothelial function was evaluated by flow mediated dilation (FMD) in the brachial artery, carotid-femoral pulse wave velocity 
(PWV) was measured as an index of aortic stiffness and augmentation index (AIx) as an index of arterial wave reflections. High on 
treatment platelet reactivity (HPR) was evaluated using VerifyNow Assay. VerifyNow reports its results in P2Y12 reaction units (PRU) and 
the diagnostic cut-off value is 230 PRU. Patients were evaluated prospectively up to 24 months. The primary end point was a composite of 
death from cardiovascular causes, nonfatal major cardiovascular events and hospitalization for cardiovascular causes.
results:  There was no difference in the basic clinical and demographic characteristics between subjects with HPR and non-HPR. Subjects 
with high on treatment platelet reactivity and PRU>230 had significantly increased PWV (8.81±2.25m/sec vs. 7.69±1.95m/sec, p=0.001), 
AIx (25.27±8.67% vs. 20.87±10.57%, p=0.04) and impaired FMD (4.54±1.97% vs. 6.77±3.35%, p=0.005) compared to subjects with 
PRU≤230. PRU was also associated with PWV (r=0.23, p=0.02) and inversely associated FMD (r=-0.265, p=0.02). HPR was associated 
with significantly increased risk of primary end point [HR=5.38, 95%CI:(1.15, 26.04), p=0.03].
Conclusion:  Increased platelet reactivity is associated with impaired endothelial function and arterial stifness in patients after 
percutaneous coronary intervention receiving clopidogrel treatment, highlighting another clinical factor implicated in individual platelet 
response to antiplatelet therapy. Moreover, increased platelet reactivity is associated with adverse outcome in these patients.
